Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical company making and marketing generic formulations, APIs and branded generics in India while exporting to the U.S., Europe, ROW and country subsidiaries, with USFDA‑approved manufacturing and a significant ANDA pipeline (cumulative 270 filings and 212 cumulative final approvals).
Q3 FY26 revenue grew 11% year‑on‑year to INR 1,876 crore, with gross margin of 72% and EBITDA before R&D at 25% of revenue; PAT before exceptional items rose 21% year‑on‑year to INR 168 crore, showing resilient operating leverage despite U.S. pricing pressure and higher R&D spend.
R&D intensity is high—around 8–9% of revenue with quarterly R&D at INR 165 crore and full‑year guidance of INR 600–650 crore—supporting a strategy focused on complex injectables, ophthalmics, peptides and early‑entry ANDA opportunities including First‑to‑File and differentiated launches.
Geographic diversification is advancing: U.S. grew modestly (6% in Q3) while EROW expanded 36% by region, API and Pfizer collaborations showing variable performance; management expects U.S. mid‑teens potential over coming years and aims to commercialize its first U.S. branded product (Pivya) in Q4 FY26.
Pharmaceuticals & Biotechnology
Pharmaceuticals
14,573 Cr
Moderate Risk
21.6
34.1
1.1
2.6
1,107.80
635.30
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockAlembic Pharmaceuticals Ltd (APLLTD) is currently trading at 741.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical company making and marketing generic formulations, APIs and branded generics in India while exporting to the U.S., Europe, ROW and country subsidiaries, with USFDA‑approved manufacturing and a significant ANDA pipeline (cumulative 270 filings and 212 cumulative final approvals). Q3 FY26 revenue grew 11% year‑on‑year to INR 1,876 crore, with gross margin of 72% and EBITDA before R&D at 25% of revenue; PAT before exceptional items rose 21% year‑on‑year to INR 168 crore, showing resilient operating leverage despite U.S. pricing pressure and higher R&D spend. R&D intensity is high—around 8–9% of revenue with quarterly R&D at INR 165 crore and full‑year guidance of INR 600–650 crore—supporting a strategy focused on complex injectables, ophthalmics, peptides and early‑entry ANDA opportunities including First‑to‑File and differentiated launches. Geographic diversification is advancing: U.S. grew modestly (6% in Q3) while EROW expanded 36% by region, API and Pfizer collaborations showing variable performance; management expects U.S. mid‑teens potential over coming years and aims to commercialize its first U.S. branded product (Pivya) in Q4 FY26.
Over the past 52 weeks, Alembic Pharmaceuticals Ltd has traded between a low of ₹635.30 and a high of ₹1,107.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Alembic Pharmaceuticals Ltd has a market capitalization of approximately 14,447.39. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Alembic Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.41 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 14,447.39 Cr, Alembic Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Alembic Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Alembic Pharmaceuticals Ltd is 21.41. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Alembic reported tentative approvals for Palbociclib capsules (75 mg, 100 mg, 125 mg), Darolutamide tablets (300 mg), and Bosutinib tablets (400 mg via sANDA).
Alembic Pharmaceuticals received final USFDA approval for its ANDA for Haloperidol Tablets USP in strengths of 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg.
The text cites USFDA final approvals for Methotrexate Injection USP, Lamotrigine ODT USP, Sumatriptan Injection USP (autoinjector), Triamcinolone Acetonide Injectable Suspension USP, Macitentan Tablets 10 mg, and Carbamazepine ER Tablets USP.
Alembic Pharmaceuticals received USFDA final approval for its ANDA for Levothyroxine Sodium Tablets USP in strengths from 25 mcg to 300 mcg.
Bearish
6
Neutral
7
Bullish
1
Bearish
22
Neutral
7
Bullish
17
Bearish
16
Neutral
0
Bullish
16
Credit Rating Reaffirmation
CARE Ratings Limited has reaffirmed Alembic Pharmaceuticals Limited's Commercial Paper rating at CARE A1+ for an amount of Rs.1,100.00 crore (press release dated 11 June 2026).
Rating Reaffirmation
Alembic Pharmaceuticals informed that CARE Ratings Ltd. on 11 June 2026 reaffirmed its Commercial Paper rating at CARE A1+ for Rs. 1,100.00 crore.
Dematerialisation window
Alembic Pharmaceuticals published a notice that a SEBI‑mandated special window (5 Feb 2026–4 Feb 2027) is open for transfer and dematerialisation of physical securities sold/purchased on or before 1 Apr 2019; transfers will be credited to demat and locked‑in for one year; shareholders to submit requests to the registrar (MUFG Jntime India Private Limited) with requisite documents.
Regulatory Approval
Alembic Pharmaceuticals received USFDA tentative approval for its ANDA for Larotrectinib Capsules 25 mg & 100 mg (generic of Vitrakvi); sole Paragraph IV first applicant and may gain 180-day exclusivity on final approval; US market est. $91M (12 months to Mar 2026).
Tentative FDA Approval
Alembic Pharmaceuticals received US FDA tentative approval for its ANDA for Larotrectinib Capsules 25 mg and 100 mg (therapeutically equivalent to Bayer's Vitrakvi); sole Paragraph IV filer may gain 180-day exclusivity; market ~US$91M (12m to Mar 2026).
Joint venture investment
Alembic Pharmaceuticals executed a shareholders' agreement to invest in newly incorporated 17989377 Canada Inc and will hold 45% (with Difgen 45% and others 10%) to commercialize pharma products in Canada.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
425.00 | 16,194 Cr | 90.35 | 4.14 | 0.00 | 5.05 | 5.47 | 2.62 | ||
846.10 | 15,091 Cr | 10.64 | 1.64 | 0.59 | 15.38 | 15.37 | 12.39 | ||
941.75 | 15,070 Cr | 37.82 | 2.12 | 0.52 | 5.62 | 6.41 | 2.56 | ||
735.50 | 14,447 Cr | 21.41 | 2.55 | 1.63 | 11.89 | 10.81 | 7.66 | ||
1345.30 | 14,074 Cr | 53.94 | 6.98 | 0.56 | 12.94 | 17.08 | 11.60 | ||
1024.85 | 12,543 Cr | 22.22 | 3.76 | 0.49 | 16.94 | 22.33 | 14.17 | ||
250.50 | 11,313 Cr | 27.07 | 3.74 | 0.36 | 13.82 | 17.37 | 10.88 | ||
| Median: 7 Co. | — | 846.10 | 14,447 Cr | 27.07 | 3.74 | 0.52 | 12.94 | 15.37 | 10.88 |
